| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial
|
Li, Jun
|
|
|
5 |
6 |
p. 548-560
|
article
|
| 2 |
Adjuvant 131I-metuximab in hepatocellular carcinoma: a new option for an old drug?
|
Vogel, Arndt
|
|
|
5 |
6 |
p. 517-519
|
article
|
| 3 |
A global perspective on oesophageal cancer: two diseases in one
|
Ho, Andrew L K
|
|
|
5 |
6 |
p. 521-522
|
article
|
| 4 |
Assessing the impact of lowering the colorectal cancer screening age to 45 years
|
Liang, Peter S
|
|
|
5 |
6 |
p. 523-524
|
article
|
| 5 |
Correction to Lancet Gastroenterol Hepatol 2020; 5: 430–31
|
|
|
|
5 |
6 |
p. e5
|
article
|
| 6 |
COVID-19 and the liver: little cause for concern
|
Bangash, Mansoor N
|
|
|
5 |
6 |
p. 529-530
|
article
|
| 7 |
COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy
|
Bhoori, Sherrie
|
|
|
5 |
6 |
p. 532-533
|
article
|
| 8 |
Eliminating HCV: a marathon, not a sprint
|
The Lancet Gastroenterology & Hepatology,
|
|
|
5 |
6 |
p. 515
|
article
|
| 9 |
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period
|
Iacucci, Marietta
|
|
|
5 |
6 |
p. 598-606
|
article
|
| 10 |
Enteric involvement in hospitalised patients with COVID-19 outside Wuhan
|
Wan, Yunle
|
|
|
5 |
6 |
p. 534-535
|
article
|
| 11 |
Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China
|
An, Ping
|
|
|
5 |
6 |
p. 525-527
|
article
|
| 12 |
Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis
|
Xiao, Yong
|
|
|
5 |
6 |
p. 528-529
|
article
|
| 13 |
Research in brief
|
Baker, Holly
|
|
|
5 |
6 |
p. 536
|
article
|
| 14 |
Risk of colorectal cancer incidence and mortality after polypectomy: a Swedish record-linkage study
|
Song, Mingyang
|
|
|
5 |
6 |
p. 537-547
|
article
|
| 15 |
SARS-CoV-2 in wastewater: potential health risk, but also data source
|
Lodder, Willemijn
|
|
|
5 |
6 |
p. 533-534
|
article
|
| 16 |
Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward
|
Green, Christopher A
|
|
|
5 |
6 |
p. 531
|
article
|
| 17 |
Sessile serrated polyps and colorectal cancer mortality
|
Meester, Reinier G S
|
|
|
5 |
6 |
p. 516-517
|
article
|
| 18 |
Stigma and irritable bowel syndrome: a taboo subject?
|
Hearn, Mark
|
|
|
5 |
6 |
p. 607-615
|
article
|
| 19 |
The effect of sleep on gastrointestinal functioning in common digestive diseases
|
Orr, William C
|
|
|
5 |
6 |
p. 616-624
|
article
|
| 20 |
The global burden of gastro-oesophageal reflux disease: more than just heartburn and regurgitation
|
Sweis, Rami
|
|
|
5 |
6 |
p. 519-521
|
article
|
| 21 |
The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|
|
|
|
5 |
6 |
p. 561-581
|
article
|
| 22 |
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|
|
|
|
5 |
6 |
p. 582-597
|
article
|
| 23 |
Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak
|
Zingone, Fabiana
|
|
|
5 |
6 |
p. 525
|
article
|
Journal description